Friday, 30 September 2011

Promoter-Binding TF Profiling Assay I

To characterise transcription factors (TFs) that bind to a specific promoter or that regulate the expression of a specific gene via its upstream promoter, two common approaches may be applied.

  • Gel shift assay with DNA binding sites of TFs that are silico-identified within the promoter.
  • Removal or knockout the binding site(s) of a specific TF in order to measure whether the expression of a promoter-linked reporter is up or down regulated. Often, a series of reporter constructs with the promoter deletions or mutations need to be made as many binding sites of one or even a few TFs may be present within a promoter.
Signosis has developed a fast method to facilitate the characterisation of promoters through a revised TF activation array. This assay will help to test whether any of the selected 48 TFs bind to the promoter or not.


The Signosis proprietary Promoter-Binding TF Profiling Array offers:
  • Multiplex Assay - A single assay permits the characterisation of the binding of 48 TFs to a specific promoter
  • Simple Procedures - Probe incubation, spin column separation, plate hybridisation, and HRP detection

Principle of the technology

In this assay, a PCR fragment containing the promoter of your interest is mixed with a set of 48 biotin-labelled oligos corresponding to 48 TFs along with an assayed sample. If unlabelled promoter DNA fragment contains a TF binding sequence, it will compete with the biotin-labelled oligo to bind to the TF in the sample, leading to a loss or reduction in biotin labelled TF/DNA complex formation. This will in turn result in either an absence or a significant reduction in signal. By comparing samples in the presence and absence of the competitor promoter DNA fragment, promoter-bound TFs can be identified.

For further information about this product, please follow this link.

Thursday, 29 September 2011

Uscn - specialist ELISA kit manufacturer

Uscn manufacture a vast portfolio of ELISA kits for targets across many different species - including human, mouse, rat, rabbit, pig, cow, guinea pig and lots more! Many of their human ELISA's are CE marked for clinical use.

Topics in which the ELISA kits fall into are extensive:
  • Cytokines
  • Haematology
  • Innate Immunity
  • Apoptosis
  • Infectious Diseases
  • Endocrine
  • Metabolism
For more information regarding any of these kits or if you are looking for a specific ELISA please contact us on for more information.

Bulk quantity discounts are available on these products so if you are interested in purchasing any of these kits in a larger quantity please email to arrange a quotation.

Tuesday, 27 September 2011

Monosan Xtra IHC and IF Antibodies

MONOSAN Xtra is a unique addendum to their regular product line. The MONOSAN Xtra range, contains over 1,200 antibodies, primarily manufactured for immunohistochemical (IHC) and Immunofluorescence (IF) use on frozen and FFPE tissue sections.
MONOSAN Xtra contains monoclonal and polyclonal antibodies for research in the following areas:

  • Cell Adhesion Molecules
  • Cell Cycle Associated Proteins
  • Cluster Differentiation Markers
  • Cytokeratins
  • Cytotoxic Drug Metabolism
  • Growth Factors and Receptors
  • Hormone Receptors and Estrogen Regulated Proteins
  • Hormones
  • In Situ Hybridisation
  • Lymphoid Markers
  • Microbiology/Virology
  • Muscles
  • Neuroscience
  • Oncoproteins
  • Oncosuppressor and Associated Proteins
  • Small and Intermediate Filaments
  • Special Interest
  • Tumour Markers
The complete selection of highly specific and exclusive antibodies is detailed on our website.

Friday, 23 September 2011


Interleukin-33, a member of the IL-1 family of cytokines, is expressed by many cell types following pro-inflammatory stimulation and is thought to be released on cell lysis. The predicted 270-amino acid human pro-IL-33 has a calculated molecular mass of 30 kDa. Whether pro-IL-33 needs to be cleaved to be active and whether caspase-1 is required is still a matter of controversy. However, it has been reported that IL-33 is biologically active in a caspase-1 independent manner. The heterodimeric IL-33 receptor complex consists of ST2 and IL-1 receptor accessory protein (IL-1rAp) and mediates signaling through the TLR domain of IL-1rAp.

Binding of IL-33 to its receptor results in the recruitment of myD88, IRAK1, and IRAK4 to the receptor complex, activating NF-κb, Iκbα and numerous MAPKs. Cell-specific variations in the IL-33 induced signaling pathway have been described, such as the requirement of TRAF6 for IRAK recruitment in fibroblasts. In addition, IL-33 may function as a transcriptional repressor mediated by the N-terminal homeobox domain. Soluble ST2 can bind IL-33 directly and acts as a decoy receptor. Taken together IL-33 may be a dual function cytokine with both extracellular and intracellular signalling, a property it shares with IL-1α.

IL-33 affects the various cell types that express membrane ST2. ST2 is selectively expressed by TH2 but not TH1 cells. IL-33 is described as a modulator of inflammation, mediating TH2 immune responses. Administration of purified IL-33 in vitro and in vivo induces TH2-associated cytokines such as IL-5 and IL-13 and reduces production of IFN-γ from TH1 cells. IL-33 is a potent inducer of pro-inflammatory cytokines and chemokines.

The ability of IL-33 to target numerous immune cell types, like TH2-like cells, mast cells and B1 cells, and to induce cytokine and chemokine production underlines its potential in influencing the outcome of wide range of diseases such as:
  • Arthritis
  • Asthma
  • Atopic Allergy and Anaphylaxis
  • Cardiovascular Diseases / Atherosclerosis
  • Nervous System Diseases
  • Sepsis

Thursday, 22 September 2011

Biomedical Science Congress

Come and visit us in Birmingham…
We are exhibiting at the annual IBMS Biomedical Science Congress held at the ICC in Birmingham. This meeting is organised by the Institute of Biomedical Sciences and is being held from 26th – 28th September 2011. We’ll be there for the entire duration of the exhibition at stand F12, located on the hall 1 foyer.
The IBMS is the professional body for biomedical scientists in the United Kingdom. It aims to promote and develop the role of biomedical science within healthcare to deliver the best possible service for patient care and safety.
The scientific topics covered at the meeting include:
To view the complete lecture programme, click here.
Go online and visit the congress website for more information. Register for the exhibition by following this link:
We look forward to seeing you there!

Monday, 19 September 2011

Smart-IP: Tag Antibodies Conjugated to Magnetic Beads for Immunprecipitation

  • Ready to use
  • No time consuming centrifugation steps
  • High recovery of beads
  • Complete removal of supernatant
MBL International Corporation introduces Smart-IP, a line of highly specific antibodies conjugated to magnetic beads. Conventional immunoprecipitation of tagged proteins requires centrifugation steps and several washing steps. Smart-IP improves efficiency by reducing time-consuming processes. The spherical, 3µm magnetic beads are covalently bound to a Tag antibody and the beads are easily isolated using a magnetic stand. The supernatant is extracted with minimal sample loss.

Available Products:

Friday, 16 September 2011


Immunohistochemistry (IHC) refers to the method of localizing specific antigens in cells or tissue sections based on the binding of labelled antibody to antigens. The antigen-antibody interaction could be visualized by a marker such as enzyme, radiolabel, fluorophore or colloidal metal. IHC makes it possible to visualize the distribution and localization of specific cellular components within a cell or tissue.

There are two methods for the immunohistochemical detection of antigens in tissue, the direct and indirect methods. The direct method, it is one-step staining with a labelled antibody reacting directly to antigen in tissue sections. This method is simple and rapid but has a lack of sensitivity. The indirect method requires the use of two antibodies. One is an unlabelled primary antibody which reacts with tissue antigen and the other is a labelled secondary antibody which reacts with this primary antibody. The indirect method is more sensitive due to several secondary antibody reactions with different antigenic sites on the primary antibody and allows for signal amplification. Abnova uses the indirect method to detect antigens in tissue.

Complete collection of IHC Validated Antibodies Include:
Angiogenesis | Apoptosis | Binding | Cell Ad/Junc/Cytoskel | Cell Cycle | Cytokine | Enzyme | Membrane | Metabolism | Neurobiology | Plasma/Serum | Stem Cell | Signal Transduction | Transcriptions | Ubiquitin | Others

Monday, 12 September 2011

Cytomark supplied by Caltag Medsystems Ltd

Cytomark is a biotechnology company dedicated to the manufacture of flow cytometry reagents.

Cytomark was formed to bring to the market blood stabilisation technologies developed by UK NEQAS who are responsible for External Quality Assurance in Blood Pathology in the UK and many other countries in Europe. The development of these technologies arose out of the need to transport whole blood samples between laboratories without any cellular degradation.
Cytomark has two blood stabilisation technologies, TransFix® for short term stabilisation and CytoFix® for longer term stabilisation. Both technologies preserve blood cells and in particular cellular markers while preserving the light scatter properties of the blood. This makes them ideal for use in conjunction with diagnostic techniques involving laser refraction such as flow cytometry.

TransFix® is a stabilisation solution that when added to peripheral blood samples, CSF, bone marrow etc. will stabilise the sample for up to 10 days. TransFix® stabilises samples at ambient temperatures of up to 37⁰C, allowing samples to be collected and transported without refrigeration. Samples can also be grouped and batched for analysis prior to transportation to the laboratory saving time and money. TransFix® has been extensively used in collection of samples for HIV/AIDS immune monitoring and is currently being tested in conjunction with diseases including malaria and TB.

CytoFix® is a manufacturing process used to manufacture whole blood controls for clinical pathology. CytoFix® whole blood controls are stable for up to 6 months when stored at 4⁰C. They can be used for external quality assurance assessment of testing laboratories and as daily run controls by individual laboratories.
CytoFix® CD4 controls have been developed for HIV/AIDS immune monitoring: CytoFix® CD4 Low (200 CD4 count) and CytoFix® CD4 Normal (>600 CD4 count). These controls have been adopted by CDC laboratories in Uganda, Kenya and Côte d’Ivoire. The benefits of these controls over other competitors are price (less than 50% of the cost of the nearest competitor) and stability (6 months shelf life) making these economical and effective products in resource poor areas of the world.

CytoFix® stabilisation technology can also be applied to any cellular solution in order to manufacture controls that are stable and consistent. Research is ongoing to develop whole blood controls for malaria in conjunction with the Liverpool School of Tropical Medicine.

For more information on Cytomark visit their website here.

Friday, 9 September 2011

Come and see us in York...

We are exhibiting at the annual Flow Cytometry course held at The University of York, hosted by The Royal Microscopical Society (RMS). The Flow Cytometry exhibition will be held on the 14th September 2011 in the Department of Biology.

The RMS is at the forefront of new ideas and developments on microscopy and imaging, and has been so for 180 years. It is the only truly international microscopical society, drawing distinguished members from all over the world.

It is dedicated to advancing science, developing careers and supporting wider understanding of science and microscopy.

The course runs from the 12th – 16th September and is constructed as a set of three modules. The modules consist of lectures interspersed with sessions in the laboratory.

For Module 1, no prior knowledge of flow cytometry is assumed. It will give you a firm grounding in the basics of flow cytometry. There is also a strong emphasis on practical application with four practical sessions included.

The later Modules assume that you have some basic knowledge of flow cytometry (which can be obtained by taking Module 1).

Module 2, Clinical Applications, will include practical sessions and lectures on applications including immunophenotyping leukaemias, quality control, applications to transplantation and blood transfusion, apoptosis, AIDS and cytokines.

Module 3, Applications in Cell Biology, will include a study of the DNA histogram and the cell cycle, measuring cell cycle kinetics in cultures and in tumours in vivo, using labelling with bromodeoxyuridine, the measurement of cell cycle related proteins, cytokines, apoptosis (including practical work) and microbiology.

Download the course programme here.

Wednesday, 7 September 2011

Come and visit us in Dublin...

We are exhibiting at the 11th Euroconference on Clinical Cell Analysis in Dublin from the 13th-17th September.

Organised by the European Society for Clinical Cell Analysis (ESCCA) and the Irish Cytometry Society (ICyS), the meeting is of major importance for education and scientific exchange in the fields of basic, translational and clinical applications in cytometry. The meeting will offer a unique opportunity to learn, to share information and scientific experience, to seek collaborations and to network - in short, to be involved and to meet old and new friends.

The conference will provide updates and discussion areas on:

  • Fallout: 25 years after the Chernobyl disaster
  • Clonal hematopoietic disorders
  • Cytometric indicators of cell activation
  • Automation in cytometry
  • Flow cytometry in pediatric diseases
  • Minimal residual disease in solid tumors
  • Novel methods & technologies in clinical cell analysis
  • Debate “How many colors are enough?”
  • 20 selected oral abstract presentations
  • 2010-2011 Clinical Cytometry best original paper
  • ESCCA Keynote lecture

Drop us a visit at Stand 23

Come along, get involved, meet new friends and see old faces.

The conference will be held at the Dublin Convention Centre for venue information and directions click here.

Download the programme here.

Tuesday, 6 September 2011

FTO - A Gene Contributing to Human Obesity

FTO (Fat mass-and obesity-associated gene) is the responsible gene for mouse ‘fused toes’ mutation. Ubiquitous over expression of FTO in mice results in increased food consumption and leads to a dose-dependent increase in obesity. An association between FTO genotype and type 2 diabetes has been confirmed.

FTO mRNA is widely expressed in different tissues, especially in the brain, but also in skeletal muscles and adipose tissue. In the mice brain, Fto is highly expressed in hypothalamic nuclei that control eating behaviour.

The presence of the FTO rs9939609 A-allele was found to be positively correlated with other symptoms of the metabolic syndrome, including higher fasting insulin, glucose, and triglycerides, and lower HDL-cholesterol.

Research also indicates that FTO, apart from correlating with obesity, also is essential for normal development in humans and might have different roles in different tissues.

Figure: Immunohistochemical staining of FTO with anti-FTO (human), mAb (FT403-2) (Prod. No. AG-20A-0075) in brain, hypothalamus and paraventricular nucleus (5~10 μg/ml).

This antibody has been tested in immunohistochemistry, analyzed by an anatomic pathologist and validated for use in IHC applications against formalinfixed, paraffin-embedded human tissues. The image shows the localization of the antibody as the precipitated red signal, with a hematoxylin purple nuclear counterstain (40x).

Thursday, 1 September 2011

Signosis Catalogues now available.

Signosis is a molecular tool company focusing on the development of innovative and unique products for biomarker discovery and analysis in life science research, clinic application and drug discovery.

The Signosis product portfolio currently includes miRNA arrays, miRNA northern blot assay kits, miRNA plate assays, phosphor-antibodies, obesity ELISA kits, cancer ELISA kits and cardiac marker ELISA kits.

Request your free Signosis Catalogue now by clicking here.

Webmaster: AnnWebCom | Site design: Creative Copyright 2005-2015 Caltag-Medsystems Limited - all rights reserved